3-hydroxykynurenine has been researched along with Huntington Disease in 11 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 6.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 2.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "3-Hydroxykynurenine was substantially and significantly increased in all three brain areas studied in Huntington's disease, but not significantly increased in the cortex in Alzheimer's disease, when compared to matched controls." | 1.28 | Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. ( Pearson, SJ; Reynolds, GP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Winkler, D | 1 |
| Beconi, M | 1 |
| Toledo-Sherman, LM | 1 |
| Prime, M | 1 |
| Ebneth, A | 1 |
| Dominguez, C | 1 |
| Muñoz-Sanjuan, I | 1 |
| Sathyasaikumar, KV | 2 |
| Stachowski, EK | 1 |
| Amori, L | 1 |
| Guidetti, P | 4 |
| Muchowski, PJ | 2 |
| Schwarcz, R | 5 |
| Campesan, S | 1 |
| Green, EW | 1 |
| Breda, C | 1 |
| Kyriacou, CP | 1 |
| Giorgini, F | 1 |
| Stone, TW | 1 |
| Mackay, GM | 1 |
| Forrest, CM | 1 |
| Clark, CJ | 1 |
| Darlington, LG | 1 |
| Bates, GP | 1 |
| Graham, RK | 1 |
| Hayden, MR | 1 |
| Leavitt, BR | 1 |
| MacDonald, ME | 1 |
| Slow, EJ | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Guilarte, TR | 1 |
| Eastman, CL | 1 |
| Reddy, PH | 1 |
| Tagle, DA | 1 |
| Pearson, SJ | 2 |
| Reynolds, GP | 2 |
2 reviews available for 3-hydroxykynurenine and Huntington Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Tryptophan metabolites and brain disorders.
Topics: AIDS Dementia Complex; Brain Diseases; Central Nervous System Diseases; Humans; Huntington Disease; | 2003 |
9 other studies available for 3-hydroxykynurenine and Huntington Disease
| Article | Year |
|---|---|
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
Topics: Animals; Cell Line; CHO Cells; Chromatography, Liquid; Cricetulus; Dogs; Drug Discovery; Enzyme Assa | 2013 |
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
Topics: Age Factors; Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; H | 2010 |
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington | 2011 |
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
Topics: Aged; Animals; Butyrates; Case-Control Studies; Cerebellum; Corpus Striatum; Frontal Lobe; Humans; H | 2003 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Is 3-hydroxykynurenine an endogenous neurotoxin in Huntington's disease?
Topics: Humans; Huntington Disease; Kynurenine; Neurotoxins | 1993 |
Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
Topics: Aged; Animals; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; Kynurenine; M | 2000 |
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
Topics: Aged; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Female; Humans; Huntingt | 1992 |
Increased brain 3-hydroxykynurenine in Huntington's disease.
Topics: Brain Chemistry; Cerebral Cortex; Humans; Huntington Disease; Kynurenine; Tryptophan | 1989 |